• Je něco špatně v tomto záznamu ?

Recent advances in drugs and prodrugs design of chitosan

J Vinsova, E Vavrikova

. 2008 ; 14 (13) : 1311-1326.

Jazyk angličtina Země Nizozemsko

Typ dokumentu přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc11003707
E-zdroje

NLK ProQuest Central od 2000-01-01 do 2008-12-31
Health & Medicine (ProQuest) od 2000-01-01 do 2008-12-31

The aim of this review is to outline the recent advances in chitosan molecular modeling, especially its usage as a prodrug or drug in a field of antibacterial, anticarcinogenic and antioxidant activity. Polymeric materials like peptides, polysaccharides and other natural products have recently attracted attention as biodegradabile drug carriers. They can optimize clinical drug application, minimize the undesirable drug properties and improve drug efficiency. They are used for the slow release of effective components as depot forms, to improve membrane permeability, solubility and site-specific targeting. Chitosan is such a prospective cationic polysaccharide which has shown number of functions in many fields, including bio medicinal, pharmaceutical, preservative, microbial and others. This article discusses the structure characteristics of chitosan, a number of factors such as degree of polymerization, level of deacetylation, types of quarternisation, installation of various hydrophilic substituents, metal complexation, and combination with other active agents. Biodegradable, non-toxic and non-allergenic nature of chitosan encourages its potential use as a carrier for drug delivery systems in all above mentioned targets. The use of chitosan prodrug conjugates is aimed at the site-specific transport to the target cells use, for example, a spacer tetrapeptide Gly-Phe-Leu-Gly, promotion of drug incorporation into cells via endocytosis, hybridization or synergism of two types of drugs or a drug with a bioactive carrier. The design of chitosan macromolecule prodrugs is also discussed.

000      
03192naa 2200409 a 4500
001      
bmc11003707
003      
CZ-PrNML
005      
20121127124552.0
008      
110302s2008 ne e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Vinšová, Jana. $7 _AN043807
245    10
$a Recent advances in drugs and prodrugs design of chitosan / $c J Vinsova, E Vavrikova
314    __
$a Faculty of Pharmacy, Charles University, Czech Republic, Heyrovskeho 1203, 500 05 Hradec Kralove. jarmila.vinsova@faf.cuni.cz
520    9_
$a The aim of this review is to outline the recent advances in chitosan molecular modeling, especially its usage as a prodrug or drug in a field of antibacterial, anticarcinogenic and antioxidant activity. Polymeric materials like peptides, polysaccharides and other natural products have recently attracted attention as biodegradabile drug carriers. They can optimize clinical drug application, minimize the undesirable drug properties and improve drug efficiency. They are used for the slow release of effective components as depot forms, to improve membrane permeability, solubility and site-specific targeting. Chitosan is such a prospective cationic polysaccharide which has shown number of functions in many fields, including bio medicinal, pharmaceutical, preservative, microbial and others. This article discusses the structure characteristics of chitosan, a number of factors such as degree of polymerization, level of deacetylation, types of quarternisation, installation of various hydrophilic substituents, metal complexation, and combination with other active agents. Biodegradable, non-toxic and non-allergenic nature of chitosan encourages its potential use as a carrier for drug delivery systems in all above mentioned targets. The use of chitosan prodrug conjugates is aimed at the site-specific transport to the target cells use, for example, a spacer tetrapeptide Gly-Phe-Leu-Gly, promotion of drug incorporation into cells via endocytosis, hybridization or synergism of two types of drugs or a drug with a bioactive carrier. The design of chitosan macromolecule prodrugs is also discussed.
650    _2
$a antibakteriální látky $x chemie $x terapeutické užití $7 D000900
650    _2
$a protinádorové látky $x chemie $x terapeutické užití $7 D000970
650    _2
$a antioxidancia $x chemie $x terapeutické užití $7 D000975
650    _2
$a chitosan $x farmakologie $x chemie $x terapeutické užití $7 D048271
650    _2
$a nosiče léků $7 D004337
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární struktura $7 D015394
650    _2
$a prekurzory léčiv $x farmakologie $x chemie $x terapeutické užití $7 D011355
650    _2
$a financování organizované $7 D005381
655    _2
$a přehledy $7 D016454
700    1_
$a Vavříková, Eva $7 xx0126311
773    0_
$t Current Pharmaceutical Design $w MED00007893 $g Roč. 14, č. 13 (2008), s. 1311-1326
910    __
$a ABA008 $b x $y 7
990    __
$a 20110413121613 $b ABA008
991    __
$a 20121127124619 $b ABA008
999    __
$a ok $b bmc $g 831106 $s 695729
BAS    __
$a 3
BMC    __
$a 2008 $b 14 $c 13 $d 1311-1326 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
LZP    __
$a 2011-3B/vtme

Najít záznam